Scenic Biotech is an Amsterdam-based company that provides genetic modifiers to enable development of disease-modifying therapeutics for rare genetic disorders and other illnesses. The company leverages its Cell-Seq genetic modifier target discovery platform to identify genetic modifiers across multiple therapeutic areas and build an in-house pipeline. Lead programs include an immuno-oncology program targeting QPCTL and three rare disease programs for Niemann‑Pick disease type C (NP‑C1), Barth syndrome, and a severe heritable metabolic syndrome. Alongside its in-house work Scenic has a multi-year, multi-indication strategic collaboration with Genentech (a member of the Roche Group) to discover, develop and commercialize novel therapeutics targeting genetic modifiers. The company plans to use its Series A proceeds to accelerate the transition into a development-stage company, advance its pipeline, and support creation of new programs and industry collaborations. Scenic anticipates more than doubling its team in the next 18 months, building clinical capabilities, and expanding its facilities within the Science Park life sciences cluster in East Amsterdam. Scenic Biotech is a therapeutics company developing genetic off-switches to target cancer and rare genetic diseases. The company leverages its Cell-Seq technology to identify disease-suppressing genes that have been difficult to uncover. Scenic emerged from research at Oxford University and the Netherlands Cancer Institute and was co-founded by Thijn Brummelkamp and Sebastian Nijman. The company is based in Amsterdam, the Netherlands. Scenic raised €6.5M in a Series A financing and will use the funds to develop its genetic off-switch programs.

Total raised

$38M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2022